At the time of writing, ImmunityBio Inc [IBRX] stock is trading at $2.82, up 8.88%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The IBRX shares have gain 31.78% over the last week, with a monthly amount glided 28.77%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
ImmunityBio Inc [NASDAQ: IBRX] stock has seen the most recent analyst activity on May 20, 2025, when Piper Sandler upgraded its rating to an Overweight but kept the price target unchanged to $5 for it. Previously, H.C. Wainwright started tracking the stock with Buy rating on March 06, 2025, and set its price target to $8. On January 10, 2025, BTIG Research initiated with a Buy rating and assigned a price target of $6 on the stock. Piper Sandler downgraded its rating to a Neutral and decreased its price target to $4 on May 12, 2023. Jefferies initiated its recommendation with a Buy and recommended $8 as its price target on August 03, 2022.
For the past year, the stock price of ImmunityBio Inc fluctuated between $1.83 and $4.27. Currently, Wall Street analysts expect the stock to reach $7 within the next 12 months. ImmunityBio Inc [NASDAQ: IBRX] shares were valued at $2.82 at the most recent close of the market. An investor can expect a potential return of 148.23% based on the average IBRX price forecast.
Analyzing the IBRX fundamentals
According to ImmunityBio Inc [NASDAQ:IBRX], the company’s sales were 82.56M for trailing twelve months, which represents an 425.07% jump. Gross Profit Margin for this corporation currently stands at 0.95% with Operating Profit Margin at -3.16%, Pretax Profit Margin comes in at -4.22%, and Net Profit Margin reading is -4.22%.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
It is important to note that ImmunityBio Inc [NASDAQ:IBRX] has a current ratio of 5.77. In addition, the Quick Ratio stands at 5.65. Considering the valuation of this stock, the price to sales ratio is 33.64.
